Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced today that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026. The meeting, held on April 23, 2026, saw the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. However, the motions for the extraordinary part of the meeting were not put to a vote because the required quorum was not reached.
The approval of the new board members marks a significant governance update for the biopharmaceutical company, which is focused on developing novel therapies for central and peripheral nervous system diseases. Chris Martin, Chairman of the Board of Directors, expressed gratitude to shareholders for their trust and welcomed the newly elected members. He also acknowledged the contributions of Patrick Langlois and Luca Benatti, who stepped down after long-standing service.
Newron's lead compound, evenamide, is a first-in-class glutamate modulator currently in the global pivotal ENIGMA-TRS Phase III development program for treatment-resistant schizophrenia (TRS) and poorly responding patients with schizophrenia. The company has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea.
Newron's first marketed product, Xadago®/safinamide, has received marketing authorization for Parkinson's disease in multiple regions, including the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by partners Zambon, Supernus Pharmaceuticals (in the U.S.), and Meiji Seika (in Japan and other key Asian territories).
For more information about Newron, visit www.newron.com. The original press release is available at www.newmediawire.com.
